Polycystic ovarian syndrome (PCOS). Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: For Intervention Group: Resveratrol (manufactured by Biovita company), Orally 1gr/day (2 Cap.) for 40 days from the beginning of the menstruation cycle till oocyte retrieval. Intervent
Treatment - Drugs
For Intervention Group: Resveratrol (manufactured by Biovita company), Orally 1gr/day (2 Cap.) for 40 days from the beginning of the menstruation cycle till oocyte retrieval.
For Control Group: Placebo of Resveratrol, Orally 2 Cap. for 40 days from the beginning of the menstruation cycle till oocyte retrieval.
Sponsors
Vice chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Infertility with documented PCOS based on Rotterdam criteria; 18-40 Y/O; If have male factor; it must be mild to moderate form, not non-obstructive azospermia; If have other female factor; only cervical & tubal factors are acceptable; Candidate for IVF Cycle; No insulin taking history; Not eating red grapes, pistachio, peanut and berries recently. Exclusion Criteria: Diseases due to obesity with unknown cause (Hypothyroidism, Coshing Syndrome); . FSH>10 at third day of the cycle; Severe endometriosis (Stage III or IV); Thyroid diseases; Congenital Adrenal Hyperplasia; Hyperprolactinemia; Ovarian Tumors; Taking Steroids, OCP and other drugs that affect ovarian function, insulin sensitivity or lipid metabolism in past 3 months (except routin PCOS therapy); SLE (Systemic Lupus Erythematosus) & autoimmune diseases; Systemic diseases like Metabolic Syndrome, Hyperlipidemias & cardiovascular diseases; Severe male factor like non-Obstructive Azospermia (sperm concentration < 5 mill/m); Patients who use vitrification method to avoid OHSS; Having alergy to some fruits like red grapes, pistachio and red berry; Insulin taking history
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ATF4 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;ATF6 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;CHOP Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;GRP78 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;XBP1 Expression. Timepoint: After follicle retrieval (Approximately 40 days after treatment). Method of measurement: Real-time relative quantification.;Inflammatory factors(IL-6, IL-18, IL-1beta, TNF-alpha, CRP). Timepoint: Before & After Intervention. Method of measurement: By ELISA Method.;Insulin Resistance factors( glucose, insulin, homocystein, QUICKI, HOMA-IR). Timepoint: Before & After Intervention. Method of measurement: By Espectrophotometry Method.;Biochemical Factors( FBS, cholestrole, Trigliseride, HDL, LDL). Timepoint: Before & After Intervention. Method of measurement: By Photometry Method.;ROS (Reactive Oxygen Species: PC & MD). Timepoint: After follicle retrieval (Approximately 40 days after treatment) , Before & After Intervention. Method of measurement: By Espectrophotometry Method.;NF-?B Expression. Timepoint: Before & After Intervention. Method of measurement: Real-time relative quantification.;TAC (Total Antioxidant Capacity). Timepoint: After follicle retrieval (Approximately 40 days after treatment) , Before & After Intervention. Method of measurement: By Espectrophotometry Method.;Number of retrieved Oocytes. Timepoint: After Intervention. Method of measurement: Count Under Microscope.;Number of retrieved Mature Oocytes (MII). Timepoint: After Intervention. Method of measurement: Count Under Microscope.;Quality of Retrieved Oocytes. Timepoint: A | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamaneh Brenjian
Tehran University of Medical sciences
Outcome results
None listed